Double maintains 3 strategies that include CRSP - CRISPR Therapeutics AG
Current Value
$52.361 Year Return
Current Value
$52.361 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VSA | -0.03% | $8.67M | -19.04% | 0.00% |
TSN | 0.07% | $20.06B | +1.50% | 3.46% |
WRB | 0.07% | $26.84B | +36.70% | 0.46% |
MSIF | -0.10% | $769.47M | +36.17% | 7.61% |
PRA | -0.15% | $1.17B | +89.68% | 0.00% |
CL | -0.23% | $74.88B | -3.64% | 2.19% |
WEC | -0.24% | $33.11B | +33.56% | 3.32% |
BULL | -0.27% | $6.47B | +25.76% | 0.00% |
BTI | 0.28% | $103.67B | +50.78% | 6.33% |
GIS | 0.29% | $29.20B | -14.66% | 4.47% |
DFDV | 0.32% | $300.56M | +2,130.16% | 0.00% |
KDP | -0.34% | $45.96B | +3.42% | 2.72% |
MCK | 0.37% | $88.11B | +20.93% | 0.40% |
GFI | 0.41% | $21.56B | +57.55% | 2.31% |
CCEC | 0.43% | $1.02B | +3.91% | 2.58% |
PG | -0.47% | $377.94B | -1.61% | 2.53% |
IMNN | -0.53% | $16.26M | -34.16% | 0.00% |
KMB | 0.56% | $43.92B | -3.75% | 3.75% |
ADC | 0.61% | $7.93B | +16.41% | 4.21% |
NEE | 0.63% | $150.32B | +1.66% | 2.95% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -19.18% | $24.23B | +35.36% | 1.09% |
ED | -16.66% | $36.00B | +12.64% | 3.34% |
MO | -14.98% | $99.67B | +28.77% | 6.90% |
CME | -14.41% | $99.39B | +40.68% | 3.86% |
DUK | -13.89% | $90.99B | +17.25% | 3.56% |
EXC | -11.61% | $43.33B | +23.58% | 3.62% |
T | -10.10% | $203.71B | +51.55% | 3.92% |
LITB | -9.80% | $21.24M | -78.57% | 0.00% |
K | -8.26% | $27.76B | +41.17% | 2.85% |
PM | -7.81% | $273.81B | +73.45% | 3.06% |
BTCT | -7.18% | $25.56M | +61.14% | 0.00% |
AWK | -7.06% | $27.36B | +9.65% | 2.21% |
PSQH | -7.04% | $98.82M | -36.55% | 0.00% |
AEP | -6.71% | $55.16B | +17.93% | 3.54% |
ZCMD | -6.70% | $29.55M | -8.59% | 0.00% |
PGR | -5.64% | $151.13B | +22.60% | 1.89% |
SO | -5.44% | $100.18B | +17.28% | 3.18% |
VHC | -4.94% | $48.19M | +108.24% | 0.00% |
KO | -4.91% | $305.22B | +11.97% | 2.81% |
AMT | -4.74% | $104.32B | +14.40% | 3.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RXRX | 72.37% | $2.12B | -29.12% | 0.00% |
BEAM | 71.28% | $2.00B | -15.33% | 0.00% |
NTLA | 67.18% | $1.11B | -53.25% | 0.00% |
ABCL | 62.26% | $1.12B | +38.38% | 0.00% |
CRBU | 61.63% | $127.42M | -14.38% | 0.00% |
ALLO | 60.47% | $262.48M | -42.31% | 0.00% |
TWST | 57.51% | $2.26B | -21.50% | 0.00% |
SITE | 56.30% | $5.78B | +9.30% | 0.00% |
DNLI | 55.30% | $2.16B | -30.05% | 0.00% |
FATE | 55.25% | $128.39M | -64.56% | 0.00% |
DNA | 53.76% | $703.03M | -15.71% | 0.00% |
EYPT | 53.08% | $664.72M | +12.07% | 0.00% |
SDGR | 52.68% | $1.54B | +4.28% | 0.00% |
COHU | 52.11% | $953.77M | -38.54% | 0.00% |
LSCC | 51.92% | $7.19B | -16.13% | 0.00% |
IMNM | 51.30% | $750.92M | -28.80% | 0.00% |
TXG | 51.20% | $1.62B | -30.61% | 0.00% |
IPGP | 50.94% | $3.12B | -13.24% | 0.00% |
EDIT | 50.52% | $214.31M | -45.06% | 0.00% |
KLIC | 49.94% | $1.94B | -25.30% | 2.20% |
Yahoo
These companies are poised to produce fireworks for your portfolio over the coming years.
Yahoo
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operat
Finnhub
CRISPR Therapeutics AG added to Russell 3000 Value Index...
Finnhub
CRISPR Therapeutics AG added to Russell 2500 Value Index...
Yahoo
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
Yahoo
ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual TIME 100 Most Influential Companies list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing. TIME highlighted CRISPR Therapeutics’ expansion beyond its landmark success in treating sickle cel
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JMBS | 0.01% | $5.55B | 0.22% |
BOND | -0.05% | $5.67B | 0.7% |
GBIL | -0.10% | $6.37B | 0.12% |
TOTL | 0.11% | $3.84B | 0.55% |
TIPZ | 0.13% | $94.79M | 0.2% |
FLDR | 0.17% | $941.22M | 0.15% |
JMST | 0.18% | $4.06B | 0.18% |
IBMP | -0.18% | $553.65M | 0.18% |
VMBS | -0.24% | $14.48B | 0.03% |
SHYD | 0.25% | $332.63M | 0.35% |
NUBD | 0.27% | $397.77M | 0.16% |
FXE | 0.31% | $568.94M | 0.4% |
SPMB | -0.32% | $6.16B | 0.04% |
IBD | -0.32% | $385.27M | 0.43% |
SCHP | -0.36% | $12.99B | 0.03% |
CGSD | -0.46% | $1.32B | 0.25% |
MMIN | -0.65% | $336.10M | 0.3% |
JBND | -0.65% | $2.32B | 0.25% |
SMMU | 0.70% | $892.02M | 0.35% |
OWNS | -0.72% | $129.31M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 79.43% | $1.02B | 0.75% |
GNOM | 75.42% | $44.57M | 0.5% |
XBI | 67.45% | $4.82B | 0.35% |
ARKK | 64.74% | $6.85B | 0.75% |
IBB | 61.09% | $5.26B | 0.45% |
IWC | 59.81% | $818.14M | 0.6% |
PBE | 59.53% | $223.19M | 0.58% |
IWO | 59.36% | $11.60B | 0.24% |
IWM | 57.41% | $63.72B | 0.19% |
KOMP | 57.36% | $2.29B | 0.2% |
VTWO | 57.35% | $12.52B | 0.07% |
VBK | 56.81% | $19.01B | 0.07% |
SCHA | 56.37% | $17.26B | 0.04% |
QQQJ | 56.33% | $621.52M | 0.15% |
ISCG | 56.33% | $681.20M | 0.06% |
KJAN | 55.98% | $287.30M | 0.79% |
VXF | 55.76% | $22.29B | 0.05% |
KJUL | 55.71% | $119.50M | 0.79% |
NUSC | 55.30% | $1.14B | 0.31% |
ESML | 55.14% | $1.84B | 0.17% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -50.39% | $296.22M | 1.43% |
VIXY | -38.28% | $164.54M | 0.85% |
TAIL | -36.78% | $99.63M | 0.59% |
IVOL | -25.60% | $347.03M | 1.02% |
SPTS | -17.72% | $5.80B | 0.03% |
FTSD | -17.53% | $231.81M | 0.25% |
LDUR | -16.31% | $929.65M | 0.5% |
SCHO | -14.49% | $11.03B | 0.03% |
UTWO | -14.30% | $379.52M | 0.15% |
FXY | -13.60% | $816.38M | 0.4% |
STPZ | -13.56% | $450.47M | 0.2% |
VGSH | -13.39% | $22.80B | 0.03% |
XONE | -13.35% | $625.28M | 0.03% |
ULST | -13.27% | $654.75M | 0.2% |
IBTG | -13.22% | $1.92B | 0.07% |
SHYM | -12.71% | $357.13M | 0.35% |
IBTH | -12.61% | $1.62B | 0.07% |
IBTI | -12.10% | $1.06B | 0.07% |
IBTJ | -11.53% | $688.19M | 0.07% |
IEI | -10.72% | $15.48B | 0.15% |